Developer docs
API playgroundTry for free, no card

Search company profiles

Immunai

Full company profile

uuid00007gh

Namestring
Immunai
Legal namestring
Immunai Inc.
Websiteurl
immunai.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Immunai is a New York-based AI-native biotechnology company founded in 2018 that maps and programs the human immune system using single-cell multiomics, machine learning, and proprietary software. Its core technology stack combines AMICA, the world's largest immune-focused harmonized single-cell database (5-6k studies, 800+ cell types, 500+ diseases, 300K+ patient samples), with the ImmunoDynamics Engine (IDE) for hypothesis generation and AMICA-OS, an AI operating system that integrates foundation AI models for biomarker discovery, patient stratification, and dose optimization. The platform delivers three solution modules: Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization.

The company sells through multi-year, custom-priced collaboration agreements with major biopharmaceutical firms, structured around upfront and milestone payments. Disclosed partners include AstraZeneca (three expanding agreements spanning oncology, immunology, inflammation, cardiovascular inflammation, neuroinflammation, and metabolic indications), Teva, Bristol Myers Squibb, and Boehringer Ingelheim, with academic collaborations supporting Mount Sinai, Weill Cornell Medicine, Harvard's MGH, and the Parker Institute. Announced deal potential across active collaborations exceeds $155M. The company also maintains offices in Israel, Switzerland, and the Czech Republic following the 2021 acquisitions of Nebion and Dropprint Genomics, and holds EU-U.S./Swiss-U.S. Data Privacy Framework certifications to support cross-border data processing.

Immunai has raised approximately $295M in total funding, including a $215M Series B in October 2021 at a valuation exceeding $1 billion, and operates with 101-250 employees under co-founder CEO Noam Solomon with scientific founders including Ansuman Satpathy, Danny Wells, and Dan Littman, plus former Pfizer CSO Mikael Dolsten on the board.

Short descriptiontext

Immunai is an AI-native biotech that maps the human immune system via single-cell multiomics and the AMICA-OS platform, selling multi-year collaboration agreements to major pharmaceutical companies for target discovery, preclinical evaluation, and clinical trial optimization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immune system mapping, single-cell multiomics, AI drug discovery, biomarker discovery, clinical trial optimization
Industry1 code
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
AI-driven single-cell multiomics platform for immune-related drug discovery
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Partnership Agreements
TypeSubscription Recurring
Description

Immunai generates revenue through multi-year collaboration agreements with pharmaceutical companies. These include upfront payments and potential milestone payments tied to research achievements, such as the AstraZeneca collaborations worth up to $18M, $85M (IBD), and $37.5M (oncology), plus the Boehringer Ingelheim agreement up to $15M and Bristol Myers Squibb partnership.

drugdiscoverytrends.com
2Drug Discovery Services
TypeProfessional Services
Description

Provides target discovery, preclinical evaluation, and clinical trial optimization services to pharmaceutical partners. The company supports decision-making along the drug discovery and development journey through its end-to-end platform.

immunai.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Enterprise pharmaceutical collaborations with negotiated terms
ModelOtherBilling cadenceMulti-year contract
Notes

Partnership values range from $15M to $85M+ depending on scope, duration, and therapeutic area. AstraZeneca oncology collaboration valued at up to $37.5M for 2026-2027; IBD collaboration worth $85M; Boehringer Ingelheim agreement up to $15M; initial AstraZeneca collaboration $18M.

drugdiscoverytrends.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1AMICA-OS
Description

AI operating system platform for immune system analysis and clinical decision support

immunai.com
+1 more record
Core offering1 text field

Immunai operates an AI-driven single-cell multiomics platform that maps the human immune system at single-cell resolution to support drug discovery and clinical development for pharmaceutical partners. Its offering combines the AMICA immune cell atlas database, the IDE AI analytical engine, and the AMICA-OS operating system to deliver target discovery, preclinical candidate evaluation, and clinical trial optimization services through multi-year enterprise collaboration agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced trial durations by up to 25%
+2 more records
Product overview1 text field

Immunai offers a unified AI-driven platform combining the AMICA-OS AI operating system, the AMICA (Annotated Multiomic Immune Cell Atlas) database, and the ImmunoDynamics Engine (IDE). The platform leverages multi-omic, single-cell technologies and machine learning to map the immune system at unprecedented scale and resolution. Three integrated solution modules—Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization—support pharmaceutical companies in making smarter choices, reducing risks, and accelerating progress in drug development.

Product and service6 records
1AMICA (Annotated Multiomic Immune Cell Atlas)
CategoryImmune cell atlas database
Description

The world's largest immune-focused, harmonized single-cell database, serving as the data foundation for drug discovery and development. Comprises high-resolution single-cell data from public and proprietary clinical cohorts and experiments across tens of millions of cells, covering 5-6k studies, 800+ cell types, 500+ diseases, and 300K+ patient samples. Used by pharmaceutical R&D teams to augment experimental data and inform immune-related drug discovery.

2ImmunoDynamics Engine (IDE)
CategoryAI analytical engine
Description

AI analytical framework designed to enhance clinical decision-making by identifying and prioritizing immune activation features in relation to biological questions and desired clinical outcomes. Provides mechanistic insights for trial arm prioritization, patient stratification biomarkers, target identification, and preclinical efficacy evaluation for pharmaceutical partners.

3AMICA-OS
CategoryAI operating system platform
Description

AI operating system that combines large-scale clinical immunology data at single-cell resolution with advanced foundation AI models. Supports biomarker discovery, patient stratification, dose optimization, and treatment-response analysis in oncology and immunology clinical development. Used by major pharmaceutical companies including AstraZeneca, Teva, Bristol Myers Squibb, and Boehringer Ingelheim.

4Target Discovery
CategoryDrug discovery solution
Description

Solution for identifying novel high-impact drug targets linked to disease using Immunai's multi-omic data generation and AI-powered analysis capabilities. Delivered to pharmaceutical partners as part of multi-year collaboration agreements to support immune-related target identification.

5Preclinical Evaluation
CategoryPreclinical development solution
Description

Solution for prioritizing the most promising drug candidates for development using Immunai's computational pipelines and ML-driven hypothesis validation. Helps pharmaceutical partners de-risk candidates before committing to expensive clinical development.

6Clinical Trial Optimization
CategoryClinical development solution
Description

Solution for better understanding drug mechanism of action, identifying the right patient groups, and determining optimal treatment strategies to maximize clinical trial success. Supports biomarker discovery, patient stratification, and dose optimization across oncology, immunology, and inflammation clinical programs.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

Multi-project collaboration valued at up to $15 million through 2027 to identify new therapeutic targets in cancer and autoimmune diseases. Combines Immunai's single-cell AI platform with Boehringer Ingelheim's drug discovery capabilities to analyze thousands of patient samples, focusing on T-cell dysfunction.

calcalistech.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-07
Description

Multi-year AI-driven oncology collaboration, the third expansion of partnership. AstraZeneca leverages AMICA-OS platform for biomarker discovery, patient stratification, and dose optimization in clinical trials. Immunai eligible to receive up to $37.5M over 2026-2027. Collaboration began in late 2022, expanded from oncology into immunology, inflammation, cardiovascular inflammation, neuroinflammation, and metabolic indications.

3Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-16
Description

AI partnership to use AMICA-OS to improve clinical development through immune system insights. Aims to analyze high-dimensional immune data from clinical studies to support drug development.

webwire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-11
Description

Grand Collaboration Initiative for Single-Cell Immune Profiling. Selected researchers receive free single-cell RNA sequencing and multi-omic data for studies across autoimmune kidney disease, T-cell redirection therapy in multiple myeloma, neoadjuvant immunotherapy in NSCLC, and immunotherapy resistance in gastric cancer.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-11
Description

Grand Collaboration Initiative for Single-Cell Immune Profiling academic partnership providing free single-cell RNA sequencing and multi-omic data to support cancer and immunology research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-11
Description

Grand Collaboration Initiative for Single-Cell Immune Profiling academic partnership with Harvard Medical School-affiliated MGH.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

$85 million collaboration renewal to develop targeted IBD therapy using AI-driven immune system mapping and cell atlas technology to identify new drug targets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-24
Description

Collaboration to build one of the largest single-cell datasets in cancer. Partnership aims to advance cancer immunotherapy research through comprehensive single-cell immune profiling.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-14
Description

Multi-year AI collaboration to enhance clinical decision making in immuno-oncology clinical trials. Partnership includes vitiligo disease mechanism and biomarker discovery for Teva's IL15 targeted antibody.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-26
Description

$18 million initial collaboration for advanced clinical trial optimization using AI to improve cancer drug trials.

11Nebion AG
Strategic tierCoreTypeOthersAnnounced on2021-07-29
Description

Acquisition of Swiss bioinformatics company Nebion to enhance target discovery and drug development capabilities. Involves integrating Nebion's data platform and curation team.

mobilehealthtimes.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immunai

AI-driven single-cell multiomics platform for immune-related drug discoveryimmunai.com

Immunai is an AI-native biotech that maps the human immune system via single-cell multiomics and the AMICA-OS platform, selling multi-year collaboration agreements to major pharmaceutical companies for target discovery, preclinical evaluation, and clinical trial optimization.

What Immunai does

Immunai is a New York-based AI-native biotechnology company founded in 2018 that maps and programs the human immune system using single-cell multiomics, machine learning, and proprietary software. Its core technology stack combines AMICA, the world's largest immune-focused harmonized single-cell database (5-6k studies, 800+ cell types, 500+ diseases, 300K+ patient samples), with the ImmunoDynamics Engine (IDE) for hypothesis generation and AMICA-OS, an AI operating system that integrates foundation AI models for biomarker discovery, patient stratification, and dose optimization. The platform delivers three solution modules: Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization.

The company sells through multi-year, custom-priced collaboration agreements with major biopharmaceutical firms, structured around upfront and milestone payments. Disclosed partners include AstraZeneca (three expanding agreements spanning oncology, immunology, inflammation, cardiovascular inflammation, neuroinflammation, and metabolic indications), Teva, Bristol Myers Squibb, and Boehringer Ingelheim, with academic collaborations supporting Mount Sinai, Weill Cornell Medicine, Harvard's MGH, and the Parker Institute. Announced deal potential across active collaborations exceeds $155M. The company also maintains offices in Israel, Switzerland, and the Czech Republic following the 2021 acquisitions of Nebion and Dropprint Genomics, and holds EU-U.S./Swiss-U.S. Data Privacy Framework certifications to support cross-border data processing.

Immunai has raised approximately $295M in total funding, including a $215M Series B in October 2021 at a valuation exceeding $1 billion, and operates with 101-250 employees under co-founder CEO Noam Solomon with scientific founders including Ansuman Satpathy, Danny Wells, and Dan Littman, plus former Pfizer CSO Mikael Dolsten on the board.

Immunai firmographics

Firmographics
Name
Immunai
Legal name
Immunai Inc.
Website
https://immunai.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Immunai is an AI-native biotech that maps the human immune system via single-cell multiomics and the AMICA-OS platform, selling multi-year collaboration agreements to major pharmaceutical companies for target discovery, preclinical evaluation, and clinical trial optimization.
Ownership category
akta.pro rank

Immunai industry classification

Industry
Product category
AI-driven single-cell multiomics platform for immune-related drug discovery
NAICS
Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Immune system mapping
  • Single-cell multiomics
  • AI drug discovery
  • Biomarker discovery
  • Clinical trial optimization

Where Immunai is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Immunai business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Partnership Agreements: Immunai generates revenue through multi-year collaboration agreements with pharmaceutical companies. These include upfront payments and potential milestone payments tied to research achievements, such as the AstraZeneca collaborations worth up to $18M, $85M (IBD), and $37.5M (oncology), plus the Boehringer Ingelheim agreement up to $15M and Bristol Myers Squibb partnership.
  2. Drug Discovery Services: Provides target discovery, preclinical evaluation, and clinical trial optimization services to pharmaceutical partners. The company supports decision-making along the drug discovery and development journey through its end-to-end platform.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise pharmaceutical collaborations with negotiated terms

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Immunai product offering

Product offering

Core offering

Immunai operates an AI-driven single-cell multiomics platform that maps the human immune system at single-cell resolution to support drug discovery and clinical development for pharmaceutical partners. Its offering combines the AMICA immune cell atlas database, the IDE AI analytical engine, and the AMICA-OS operating system to deliver target discovery, preclinical candidate evaluation, and clinical trial optimization services through multi-year enterprise collaboration agreements.

Product overview

Immunai offers a unified AI-driven platform combining the AMICA-OS AI operating system, the AMICA (Annotated Multiomic Immune Cell Atlas) database, and the ImmunoDynamics Engine (IDE). The platform leverages multi-omic, single-cell technologies and machine learning to map the immune system at unprecedented scale and resolution. Three integrated solution modules—Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization—support pharmaceutical companies in making smarter choices, reducing risks, and accelerating progress in drug development.

Differentiator

Problem solved

Functional benefit

Brands

  • AMICA-OS: AI operating system platform for immune system analysis and clinical decision support
  • AMICA

Products and services

  • AMICA (Annotated Multiomic Immune Cell Atlas) The world's largest immune-focused, harmonized single-cell database, serving as the data foundation for drug discovery and development. Comprises high-resolution single-cell data from public and proprietary clinical cohorts and experiments across tens of millions of cells, covering 5-6k studies, 800+ cell types, 500+ diseases, and 300K+ patient samples. Used by pharmaceutical R&D teams to augment experimental data and inform immune-related drug discovery.
  • ImmunoDynamics Engine (IDE) AI analytical framework designed to enhance clinical decision-making by identifying and prioritizing immune activation features in relation to biological questions and desired clinical outcomes. Provides mechanistic insights for trial arm prioritization, patient stratification biomarkers, target identification, and preclinical efficacy evaluation for pharmaceutical partners.
  • AMICA-OS AI operating system that combines large-scale clinical immunology data at single-cell resolution with advanced foundation AI models. Supports biomarker discovery, patient stratification, dose optimization, and treatment-response analysis in oncology and immunology clinical development. Used by major pharmaceutical companies including AstraZeneca, Teva, Bristol Myers Squibb, and Boehringer Ingelheim.
  • Target Discovery Solution for identifying novel high-impact drug targets linked to disease using Immunai's multi-omic data generation and AI-powered analysis capabilities. Delivered to pharmaceutical partners as part of multi-year collaboration agreements to support immune-related target identification.
  • Preclinical Evaluation Solution for prioritizing the most promising drug candidates for development using Immunai's computational pipelines and ML-driven hypothesis validation. Helps pharmaceutical partners de-risk candidates before committing to expensive clinical development.
  • Clinical Trial Optimization Solution for better understanding drug mechanism of action, identifying the right patient groups, and determining optimal treatment strategies to maximize clinical trial success. Supports biomarker discovery, patient stratification, and dose optimization across oncology, immunology, and inflammation clinical programs.

Quantifiable outcome

  • Reduced trial durations by up to 25%
  • +2 more outcomes

Companies that use Immunai

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Immunai technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Immunai partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and flagship.

  • Boehringer IngelheimcoreStrategic or Co-development Partner · 25 June 2026Multi-project collaboration valued at up to $15 million through 2027 to identify new therapeutic targets in cancer and autoimmune diseases. Combines Immunai's single-cell AI platform with Boehringer Ingelheim's drug discovery capabilities to analyze thousands of patient samples, focusing on T-cell dysfunction.
  • AstraZenecaflagshipStrategic or Co-development Partner · 7 May 2026Multi-year AI-driven oncology collaboration, the third expansion of partnership. AstraZeneca leverages AMICA-OS platform for biomarker discovery, patient stratification, and dose optimization in clinical trials. Immunai eligible to receive up to $37.5M over 2026-2027. Collaboration began in late 2022, expanded from oncology into immunology, inflammation, cardiovascular inflammation, neuroinflammation, and metabolic indications.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 16 January 2026AI partnership to use AMICA-OS to improve clinical development through immune system insights. Aims to analyze high-dimensional immune data from clinical studies to support drug development.
  • Mount SinaicoreStrategic or Co-development Partner · 11 January 2026Grand Collaboration Initiative for Single-Cell Immune Profiling. Selected researchers receive free single-cell RNA sequencing and multi-omic data for studies across autoimmune kidney disease, T-cell redirection therapy in multiple myeloma, neoadjuvant immunotherapy in NSCLC, and immunotherapy resistance in gastric cancer.
  • Weill Cornell MedicinecoreStrategic or Co-development Partner · 11 January 2026Grand Collaboration Initiative for Single-Cell Immune Profiling academic partnership providing free single-cell RNA sequencing and multi-omic data to support cancer and immunology research.
  • Massachusetts General Hospital (Harvard)coreStrategic or Co-development Partner · 11 January 2026Grand Collaboration Initiative for Single-Cell Immune Profiling academic partnership with Harvard Medical School-affiliated MGH.
  • AstraZenecaflagshipStrategic or Co-development Partner · 16 October 2025$85 million collaboration renewal to develop targeted IBD therapy using AI-driven immune system mapping and cell atlas technology to identify new drug targets.
  • Parker InstitutecoreStrategic or Co-development Partner · 24 April 2025Collaboration to build one of the largest single-cell datasets in cancer. Partnership aims to advance cancer immunotherapy research through comprehensive single-cell immune profiling.
  • TevacoreStrategic or Co-development Partner · 14 November 2024Multi-year AI collaboration to enhance clinical decision making in immuno-oncology clinical trials. Partnership includes vitiligo disease mechanism and biomarker discovery for Teva's IL15 targeted antibody.
  • AstraZenecaflagshipStrategic or Co-development Partner · 26 September 2024$18 million initial collaboration for advanced clinical trial optimization using AI to improve cancer drug trials.
  • Nebion AGcoreOthers · 29 July 2021Acquisition of Swiss bioinformatics company Nebion to enhance target discovery and drug development capabilities. Involves integrating Nebion's data platform and curation team.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Immunai competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

Immunai social profiles

Digital presence

Immunai compliance and trust

Trust signal

Compliance1 record

Immunai financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immunai leadership team

Management profile

Number of profiles

Profiles10 records

Immunai subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Immunai funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immunai M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunai

What does Immunai do?

Immunai operates an AI-driven single-cell multiomics platform that maps the human immune system at single-cell resolution to support drug discovery and clinical development for pharmaceutical partners. Its offering combines the AMICA immune cell atlas database, the IDE AI analytical engine, and the AMICA-OS operating system to deliver target discovery, preclinical candidate evaluation, and clinical trial optimization services through multi-year enterprise collaboration agreements.

Is Immunai a public or private company?

Immunai is a private company. It is classified as venture growth investor backed and is currently operating.

When was Immunai founded?

Immunai was founded in 2019. It employs 101 to 250 people.

Where is Immunai based?

Immunai is headquartered in New York, United States, in the North America region.

How does Immunai make money?

Two revenue lines are on record. Pharmaceutical Partnership Agreements are the primary driver. The others are drug Discovery Services.

Does Immunai have an API?

No public API is recorded for Immunai.

What industry is Immunai in?

Immunai's product category is AI-driven single-cell multiomics platform for immune-related drug discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyImmunai and Boehringer partner to identify T-cell targetsImmunai and Boehringer Ingelheim have entered a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases using Immunai's single-cell AI platform. The initial phase of the partnership is valued at up to $15 million and runs through 2027, with potential expansion based on scientific milestones. Confirmed findings will move to Immunai's laboratory facilities where they could serve as foundations for new drug discovery projects within Boehringer Ingelheim's portfolio.Let's Data ScienceImmunai Signs Discovery Deal With Boehringer IngelheimIsraeli-founded AI biotech Immunai announced a discovery collaboration with German drugmaker Boehringer Ingelheim, valued at up to $15 million and running through 2027. Under the agreement, Immunai will apply its single-cell AI platform to analyze T cells from thousands of patient samples across cancer and autoimmune diseases to identify shared patterns of T-cell dysfunction, with promising targets undergoing validation at its New York facility. Boehringer may expand the partnership if scientific progress warrants.The Jerusalem PostIsraeli-founded AI biotech Immunai launches drug-discovery collaborationIsraeli-founded AI biotech Immunai announced a drug discovery collaboration with German pharmaceutical giant Boehringer Ingelheim to identify novel T-cell targets across immuno-oncology and autoimmune diseases, valued at up to $15 million and running through 2027. The partnership will apply Immunai's single-cell AI platform to thousands of patient samples to uncover patterns of T-cell dysfunction that could serve as starting points for new drug targets. The collaboration is designed to examine both cancer immunology and autoimmune disease together, bridging research that has historically been conducted separately in these fields.CTechImmunai signs up to $15 million research pact with Boehringer IngelheimImmunai, an AI-driven biotechnology company, has entered a multi-project collaboration with German pharmaceutical group Boehringer Ingelheim to identify new therapeutic targets in cancer and autoimmune diseases. The agreement, valued at up to $15 million and running through 2027, will combine Immunai's single-cell AI platform with Boehringer Ingelheim's drug discovery capabilities to analyze thousands of patient samples. The partnership focuses on studying T-cell dysfunction as a common mechanism underlying both conditions, with promising findings potentially leading to future drug discovery programs within Boehringer Ingelheim's research portfolio.The Pharma LetterBoehringer Ingelheim teams with Immunai to find T-cell targets using AIBoehringer Ingelheim has entered a multi-project research collaboration with New York-based Immunai to identify T-cell targets in oncology and autoimmune disease, worth up to $15 million through 2027. The partners plan to analyze thousands of patient samples using Immunai's AMICA-OS artificial intelligence platform and single-cell immune profiling, with the possibility of expanding the collaboration if the work progresses.WebWireBoehringer Ingelheim Launches Discovery Collaboration with Immunai to Identify Novel T-Cell Targets Across Oncology and Autoimmune DiseaseBoehringer Ingelheim and Immunai announced a multi-project discovery collaboration focused on identifying novel T-cell targets across oncology and autoimmune diseases. The initial phase, valued at up to $15 million through 2027, will apply Immunai's single-cell AI platform to thousands of patient samples to uncover T-cell dysfunction patterns that traditional siloed approaches may miss. The collaboration aims to bridge historically separate cancer and autoimmune research fields to generate actionable targets for Boehringer Ingelheim's drug discovery portfolio.FierceBiotechWith $15M discovery deal, Boehringer becomes latest Big Pharma to buy into Immunai’s AI platformBoehringer Ingelheim has entered a discovery deal with Immunai worth up to $15 million through 2027 to identify new drug targets on dysfunctional T cells associated with cancers and autoimmune diseases. The partnership will leverage Immunai's single-cell AI platform and wet lab capabilities to analyze patient samples and validate therapeutic targets before advancing to drug programs. This marks Immunai's third Big Pharma partnership this year, following agreements with Bristol Myers Squibb and an expanded AstraZeneca deal worth $37.5 million.DrugdiscoverytrendsImmunai’s digital ‘plumbing’ keeps AstraZeneca coming backImmunai, a startup developing a foundation model of the human immune system, has expanded its oncology collaboration with AstraZeneca for the third time, with the company eligible to receive up to $37.5 million over 2026 and 2027 under the new agreement that extends its AMICA-OS platform deeper into AstraZeneca's clinical development pipeline. The collaboration, which began in late 2022 and traces back approximately five years, has expanded from immune oncology into immunology, inflammation, cardiovascular inflammation, neuroinflammation, and metabolic indications. The expanded partnership reflects Immunai's positioning as infrastructure addressing data bottlenecks in drug development, with AstraZeneca running more than 100 Phase 3 studies across multiple therapeutic areas.ynetnewsImmunai expands AstraZeneca collaboration in deal worth up to $37.5 millionImmunai expanded its collaboration with AstraZeneca in a deal worth up to $37.5 million through 2026 and 2027, extending their multiyear partnership in oncology clinical development. Under the agreement, AstraZeneca will continue using Immunai's AMICA-OS AI operating system, which combines large-scale clinical immunology data with AI models for oncology drug development including biomarker discovery, patient stratification, and dose optimization. The expansion builds on prior collaborations from 2024 and 2025, including work in inflammatory bowel disease.